On April 1, 2021, Xie, Yinong; Babiss, Lee E. published a patent.SDS of cas: 98138-75-1 The title of the patent was Preparation of SHP2 inhibitors for treatment of cancer. And the patent contained the following:
Disclosed are compounds of formula I, useful as inhibitors of protein tyrosine phosphatase SHP2 for the treatment of cancer. Compounds of formula I [wherein X = S; Ring A = (un)substituted aryl having 6-10 carbons, (un)substituted 5- to 6-membered mono-cyclic heteroaryl, or (un)substituted bicyclic ring system having 5-10 ring carbons; RA and RB independently = H or C1-12 hydrocarbyl, or N(RA)(RB) optionally = substituted heterocyclic ring system] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Thus, disubstituted 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one II was prepared from a multistep synthesis (preparation given). Exemplified I were evaluated for inhibition of SHP2 from which II demonstrated an IC50 = ≤ 50 nM. The pharmaceutical compositions comprising compounds of Formula I, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).SDS of cas: 98138-75-1
The Article related to dihydropyrazolopyrimidinone preparation shp2 inhibitor preparation inhibitor cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 98138-75-1
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics